anti-Anti-Mullerian Hormone Receptor, Type II (AMHR2) Antibodies

Cow (Bovine) Anti-Mullerian Hormone Receptor, Type II (AMHR2) interaction partners

1. Results from these studies indicate that AMH signaling via AMHR2 plays a role in both regulating granulosa cell proliferation and preventing granulosa cells from 5- to 8-mm follicles from undergoing premature differentiation before follicle selection.

2. These findings indicate the followings: AMH mRNA levels decrease in both dominant and secondary follicles during follicular deviation; granulosa cells from heathy follicles express more AMH mRNA compared to subordinate follicles undergoing atresia and FSH stimulates AMH and AMHR2 mRNA expression in granulosa cells of co-dominant follicles.

Rhesus Monkey Anti-Mullerian Hormone Receptor, Type II (AMHR2) interaction partners

1. AMH, co-expressed with AMHR2, was produced heterogeneously by preantral follicles in macaques with levels correlated positively with follicle growth and oocyte maturation. AMH may serve as a biomarker for primate follicular development in vitro.

Horse (Equine) Anti-Mullerian Hormone Receptor, Type II (AMHR2) interaction partners

1. Sertoli cell maturation during puberty in the stallion was accompanied by a reduced expression of anti-Mullerian hormone and its receptor, arrest of cell proliferation, increased expression of androgen receptor

Human Anti-Mullerian Hormone Receptor, Type II (AMHR2) interaction partners

1. Data show that anti-Mullerian hormone receptor type 2 (AMHR2) homozygous mutation was found in both cases.

2. AMHR2 single nucleotide polymorphism is not associated with Endometriosis-associated infertility.

3. In granulosa cells from women with PCOS, the regulation of AMH and AMHR2 expression is altered in a way that promotes the overexpression of the AMH/AMHR2 system, and could contribute to the follicular arrest observed in these patients.

4. genetic variants of AMH or AMHR2 were not found to be associated with a higher risk for polycystic ovaries syndrome.

5. AMHRII 1749C > T and -482A > G genetic variants are associated with the ovarian response to standard gonadotropin stimulation, affecting mainly the follicular growth in IVF.

6. Genotyping of the AMH c.146G>T and AMHR2 -482A>G polymorphisms does not provide additional useful information as a predictor of ovarian reserve or ovarian response and treatment outcomes.

7. The aim of this study was to investigate the density and distribution of single nucleotide polymorphisms (SNPs) anti-Mullerian hormone (AMH) and AMHRII receptors in cryptorchid patients.

8. No evidence of significant associations of Ile49Ser and -482A>G with reproductive outcomes and polycystic ovary syndrome.

9. a result of VEGF misregulation, AMHR2 overexpression increases AMH binding, which may attenuate follicular or oocyte maturation.

10. -482A > G genotype not associated with estradiol levels, ovarian parameters, menstrual cycle length, or pregnancy outcomes in healthy Singapore women

11. Neither AMH nor AMHR2 polymorphisms were related to age, BMI, hormone levels or ovarian parameters in the follicular phase in women of late reproductive stage.

12. There is no association between single nucleotide polymorphisms in the AMH/AMHR2 signaling pathway and early ovarian hyperstimulation syndrome in Han Chinese women

13. A significant subset of GnRH neurons express the AMH receptor.

14. A significant portion of AMHRII was missing most of its extracellular domain (ECD) and was unfolded and retained in the endoplasmic reticulum.

15. study demonstrated for the first time that human placenta and fetal membranes express and co-localize Anti-Mullerian hormone(AMH) and Anti-Mullerian hormone Receptor II

16. AMHR2 rs11170555 and rs3741664 were positively associated with AMH, estradiol and FSH levels.

17. There was evidence that in specific subgroups of women undergoing IVF/ICSI, AMH and AMHRII SNPs may be related to patients' characteristics and controlled ovarian stimulation and pregnancy outcome

18. These findings suggest that patients with primary ovarian insufficiency in China share AMH and AMHR2 genetic variants with those who go through menopause at a normal age.

19. Data indicate that Muellerian inhibiting substance type II receptor (MISRII) is a promising target for the control of ovarian granulosa cell tumors (GCT) and epithelial ovarian cancers (EOC).

20. The possible involvement of AMHRII -482 A>G polymorphism on the malfunction of follicular development in Japanese women.

Mouse (Murine) Anti-Mullerian Hormone Receptor, Type II (AMHR2) interaction partners

1. lncRNA-Amhr2 plays a role in Amhr2 gene activation in ovarian granulosa cells by enhancing promoter activity, providing insight into Amhr2 gene regulation underlying the AMH signaling in the female reproductive system.

2. A significant subset of GnRH neurons express the AMH receptor and AMH potently activates the GnRH neuron firing.

3. physiological function(s) of type 2 anti-Mullerian hormone receptor

4. Wt1 is an activator of Amhr2.